Sbir phase 1 - topic 394 - combinatory treatment modalities utilizing radiation to locally activate or release systemically delivered therapeutics.
Ended Definitive Contract Awarded Last action
- Contract number
- 75N91019C00015
- Awardee
-
Zymeron Corporation UEI GAMMMRQ6QMN1
- Awarding agency
-
National Cancer Institute
National Institutes of Health, Department of Health and Human Services
- Obligated
- $299,998
Award facts
- Opportunity
-
- PHS20191 Solicitation number
- Contract value 100% obligated
- $299,998.00 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 541715 Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)
- Set-aside
- Total Small Business
- Competition
- Full and Open Competition after exclusion of sources · 6 offers Negotiated Proposal / Quote
- Pricing
- Firm Fixed Price
- Place of performance
- Durham, NC 27709, USA
- Research
- SBIR Program Phase I Action
Award details come from SAM.gov/FPDS.
Transactions
| Action | Obligated | Date |
|---|---|---|
| Other Administrative Action | $0 | |
| Change Order | $0 | |
| Change Order | $0 | |
| Original award | $299,998 |
About this award
This is a $299,998.00 Firm Fixed Price contract awarded by the Department of Health and Human Services' National Institutes of Health National Cancer Institute to Zymeron Corporation, a Minority Owned small business, under the Small Business Innovation Research (SBIR) program. The contract is for Phase I research and development related to "Combinatory Treatment Modalities Utilizing Radiation to Locally Activate or Release Systemically Delivered Therapeutics", as part of SBIR Topic 394. Zymeron, a research-based biotechnology company, has previously supported federal agencies like the Department of Defense, Department of Health and Human Services, and Department of Energy with medical research, engineering services, IT solutions, and innovative biotech products focused on areas such as radiation exposure treatments, wound healing, and infectious disease diagnostics and therapies.
Quick answers
Who was awarded contract 75N91019C00015?
75N91019C00015 was awarded to Zymeron Corporation by National Cancer Institute (National Institutes of Health) on September 9, 2019.
How much is contract 75N91019C00015 worth?
The government has obligated $299,998 on 75N91019C00015.
Was contract 75N91019C00015 competed?
The extent of competition for 75N91019C00015 was full and open competition after exclusion of sources. The government received 6 offers. It was set aside: Total Small Business.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award